|
|
Article: PuriCore Q3 Interim Management Statement.
- Article from:
- Blood Weekly
- Article date:
- November 19, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PuriCore (LSE: PURI), the life sciences company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, today issues an Interim Management Statement covering the three-month and nine-month periods ending September 30, 2009. Financial Results (unaudited) Q3 sales of $10.6 million (2008: $8.4 million), an increase of 25% (35% increase at constant currency)
US Food Safety revenue increased 10% to $5.8 million
UK Endoscopy (including Sterilox business and Labcaire Systems) revenue increased 52% to $4.6 million (78% at ...